RGC-32 as a potential biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosis-Reference-Cited by-同舟云学术

RGC-32 as a potential biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosis

Published:2015-12 Issue:3 Volume:99 Page:498-505
ISSN:0014-4800
Container-title:Experimental and Molecular Pathology
language:en
Short-container-title:Experimental and Molecular Pathology

Author:

Kruszewski Adam M.,Rao Gautam,Tatomir Alexandru,Hewes Daniel,Tegla Cosmin A.,Cudrici Cornelia D.,Nguyen Vingh,Royal Walter,Bever Christopher T.,Rus Violeta,Rus Horea

Funder

Teva Neuroscience

Veterans Administration Merit

Foundation of the Consortium of Multiple Sclerosis Centers' MS Workforce of the Future

University of Maryland School of Medicine Office of Student Research

Leslie B. Barnett Memorial Student Fellowship

Publisher

Elsevier BV

Subject

Clinical Biochemistry,Molecular Biology,Pathology and Forensic Medicine

Reference22 articles.

1. Death ligands and autoimmune demyelination;Aktas;Neuroscientist,2006

2. Molecular cloning and characterization of RGC-32, a novel gene induced by complement activation in oligodendrocytes;Badea;J. Biol. Chem.,1998

3. RGC-32 increases p34CDC2 kinase activity and entry of aortic smooth muscle cells into S-phase;Badea;J. Biol. Chem.,2002

4. Response gene to complement 32 is required for C5b-9 induced cell cycle activation in endothelial cells;Fosbrink;Exp. Mol. Pathol.,2009

5. A longitudinal study of MRI-detected atrophy in secondary progressive multiple sclerosis;Furby;J. Neurol.,2010

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multiple sclerosis disease activity, a multi-biomarker score of disease activity and response to treatment in multiple sclerosis;Frontiers in Immunology;2024-06-27

2. Free complement and complement containing extracellular vesicles as potential biomarkers for neuroinflammatory and neurodegenerative disorders;Frontiers in Immunology;2023-01-20

3. Role of RGC-32 in multiple sclerosis and neuroinflammation – few answers and many questions;Frontiers in Immunology;2022-09-12

4. Co-occurrence between hereditary angioedema and multiple sclerosis: Therapeutic management of both diseases with fingolimod;Clinical Neurology and Neurosurgery;2022-05

5. Therapeutic approaches targeting CD95L/CD95 signaling in cancer and autoimmune diseases;Cell Death & Disease;2022-03-17